Virtus ETF Advisers LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 944 shares of the biopharmaceutical company’s stock after selling 303 shares during the period. Virtus ETF Advisers LLC’s holdings in Regeneron Pharmaceuticals were worth $527,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in REGN. ARK Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 169.8% in the 1st quarter. ARK Investment Management LLC now owns 1,218,970 shares of the biopharmaceutical company’s stock valued at $576,743,000 after acquiring an additional 767,152 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Regeneron Pharmaceuticals by 31.6% in the 1st quarter. JPMorgan Chase & Co. now owns 3,035,655 shares of the biopharmaceutical company’s stock valued at $1,436,290,000 after acquiring an additional 728,261 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Regeneron Pharmaceuticals by 351.5% in the 1st quarter. Acadian Asset Management LLC now owns 425,374 shares of the biopharmaceutical company’s stock valued at $201,262,000 after buying an additional 331,154 shares during the last quarter. Putnam Investments LLC grew its holdings in Regeneron Pharmaceuticals by 54.6% in the 1st quarter. Putnam Investments LLC now owns 655,652 shares of the biopharmaceutical company’s stock valued at $310,215,000 after buying an additional 231,463 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its holdings in Regeneron Pharmaceuticals by 33.6% in the 1st quarter. Neuberger Berman Group LLC now owns 755,789 shares of the biopharmaceutical company’s stock valued at $357,414,000 after buying an additional 190,230 shares during the last quarter. 82.31% of the stock is owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals stock traded down $6.16 during trading on Friday, reaching $647.02. 3,549 shares of the company were exchanged, compared to its average volume of 871,542. The company has a quick ratio of 3.04, a current ratio of 3.57 and a debt-to-equity ratio of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $441.00 and a twelve month high of $686.62. The business has a 50-day moving average price of $624.05 and a 200-day moving average price of $544.37. The firm has a market capitalization of $69.20 billion, a price-to-earnings ratio of 11.63, a P/E/G ratio of 0.77 and a beta of 0.16.
A number of research firms have issued reports on REGN. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $670.00 to $700.00 and gave the company an “overweight” rating in a report on Wednesday. Barclays lifted their price objective on Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the stock an “overweight” rating in a report on Friday, August 6th. UBS Group assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, September 9th. They set a “buy” rating and a $763.00 price objective on the stock. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $576.00 to $606.00 and gave the stock an “equal weight” rating in a report on Tuesday, September 7th. Finally, SVB Leerink lifted their price objective on Regeneron Pharmaceuticals from $641.00 to $725.00 and gave the stock an “outperform” rating in a report on Friday, August 6th. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $691.65.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 9,704 shares of the firm’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $648.16, for a total value of $6,289,744.64. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider George Yancopoulos sold 80,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, June 21st. The stock was sold at an average price of $538.90, for a total value of $43,112,000.00. Following the completion of the transaction, the insider now directly owns 987,483 shares of the company’s stock, valued at $532,154,588.70. The disclosure for this sale can be found here. Insiders have sold 377,092 shares of company stock worth $232,720,961 in the last quarter. 11.84% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Featured Article: Operating Income
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.